Highest-materiality recent filing
Medicus signs co-development license with Pfizer for CD228V ADC; $1B milestones
Exclusive worldwide license from Pfizer to develop/commercialize CD228V, an early-stage antibody-drug conjugate targeting CD228.
Issued two secured promissory notes to Streeterville Capital: A-1 ($12.86M principal, net $12M) and B ($10M in DACA), maturing in 18 months.
Medicus Pharma receives Nasdaq bid price deficiency notice; expands ATM to $50M
Nasdaq notified Medicus on April 21, 2026 that its stock bid price closed below $1.00 for 30 consecutive business days, non-compliant with Listing Rule 5550(a)(2).
Medicus Pharma enters $5.1M warrant inducement; issues new warrants for 4M shares
Gross proceeds ~$5.1M from exercise of 2,680,000 existing warrants at amended price of $1.92/share.
Medicus Pharma appoints Carolyn Bonner as CFO; Jim Quinlan resigns for health reasons
James Quinlan resigned as CFO effective Nov 28, 2025, after medical leave since Sep 12, 2025.
Medicus Pharma Q3 net loss $16M, pipeline advances with SkinJect and Teverelix
Net loss $16.0M in Q3 2025 vs $2.3M in Q3 2024; R&D $1.7M, G&A $5.0M.
Medicus Pharma secures $8M non-dilutive debenture from Yorkville; net proceeds $5.7M
$8M principal, 8% interest, matures Sept 2026; monthly installments of $650k plus accrued interest.
Medicus Pharma completes Antev acquisition for ~$3M cash + 1.6M shares; up to $65M contingent
Acquired 98.6% of Antev for ~$3.0M cash and 1,603,164 MDCX shares; up to $65M in contingent milestones tied to FDA Phase 2 and NDA approvals.
Medicus Pharma: FDA accepts Type C meeting; Phase 2 BCC study >75% randomized; Q2 net loss $6.2M
FDA accepted Type C meeting request; written queries submitted, response expected before end of Q3 2025.
Medicus Pharma hires Deloitte to find out-licensing partner for D-MNA (BCC)
Deloitte appointed exclusive lead financial adviser for out-licensing D-MNA for basal cell carcinoma.
Medicus Pharma enters warrant inducement for $3.75M gross; also sells $1.52M shares via SEPA
Holder exercises 1.34M existing warrants at $2.80; receives 2.68M new warrants at $3.75 expiring in 5 years.
Medicus Pharma signs share exchange agreement to acquire Antev Limited
Agreement to acquire all Antev Shares; Antev becomes wholly-owned subsidiary of Medicus.
Medicus will issue 2,666,600 common shares (~17% of outstanding) to acquire all Antev shares on a fully diluted basis.
Medicus Pharma appoints Andrew Smith COO; Phase 2 BCC trial randomized >50 of 90 patients
Andrew Smith appointed COO effective June 30, 2025; base salary $325K, 100k stock options at $2.60 vesting quarterly over 5 years.
Medicus Pharma dismisses EisnerAmper, engages KPMG as auditor
Dismissed EisnerAmper on June 3, 2025; engaged KPMG on June 4, 2025.
Medicus Pharma prices $7M public offering of 2.26M units at $3.10/unit; closes June 2
Gross proceeds $7,006,000 from 2,260,000 units at $3.10/unit; each unit = 1 common share + 1 warrant.
Medicus Pharma issues up to $5M debentures to Yorkville at 8% interest, 90% of face value
Initial closing of $1.25M debentures; two additional tranches of $1.25M and up to $2.5M subject to conditions.
Medicus Pharma (MDCX) to acquire Antev Ltd. in share exchange; up to $65M in milestones
Consideration: 2,666,600 Medicus shares (~19% stake) plus up to US$65M contingent on FDA Phase 2/NDA approvals.
Medicus Pharma enters $15M equity purchase agreement with Yorkville; plans TSXV delisting
Standby Equity Purchase Agreement with Yorkville for up to $15M over 36 months; shares sold at 97% of market price.
On June 23, 2025, Medicus Pharma Ltd. (the "Company") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO").
Max materiality 0.90 · Median 0.60 · Most common event other_material